Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Andy Smith

Latest From Andy Smith

Stock Watch: Is Oncology Still King?

Big pharmaceutical oncology franchise sales generally grew in the third quarter of 2023, but some were transitioning through loss of exclusivity and others were not being helped by their most innovative therapies.

Stock Watch Sales & Earnings

Stock Watch: Where Novo And Lilly Lead, Others Follow

AstraZeneca is the latest GLP-1 agonist aspirant after Novo’s and Lilly’s recent earnings season successes. Already, a segmentation of potential patients and frantic competition among new GLP-1 agonists and drug combinations are emerging.

Stock Watch Sales & Earnings

Stock Watch: After The Pandemic, Different Vaccines To The Rescue

From the unfavorable comparisons brought about by lower pandemic-related product sales, vaccines for other diseases bring hopes for longer-term success.

Stock Watch Sales & Earnings

Stock Watch: Novartis Softens Up The Market For BMS And Sanofi

Earnings season was not going too badly until a spate of self-inflicted wounds by BMS and Sanofi soured sentiment. Many new product launches remained too small to help.

Stock Watch Sales & Earnings

Stock Watch: Oncology Heritage Impedes Roche's Growth

Once a cancer drug powerhouse, Roche’s newer oncology launches were not taking up the slack caused by biosimilar competition to its former blockbusters. Something else was required.

Stock Watch Sales & Earnings

Stock Watch: Positive Q3 For Johnson & Johnson Post-Kenvue

J&J’s separation from its consumer division increased its cash, reduced its share count and provided interest income greater than third-quarter worldwide sales of some of its new drugs.

Stock Watch Sales & Earnings
See All